期刊文献+

亚临床甲状腺功能减退大鼠骨代谢改变及左旋甲状腺素疗效 被引量:15

Change of bone metabolism in subclinical hypothyroidism rats and the improvement of L-thyroxine treatment
下载PDF
导出
摘要 目的探讨亚临床甲状腺功能减退(SCH)模型大鼠骨代谢改变及应用左旋甲状腺素(L-T4)治疗后的疗效。方法健康Wistar雄性大鼠60只,随机分为3组:亚临床甲减组(SCH组)、L-T4替代治疗组(SCH+T4组)、对照组(C组),每组20只。测定不同组别大鼠血清血脂、骨碱性磷酸酶(BALP)、抗酒石酸酸性磷酸酶(TRACP-5b)和骨密度(BMD)。比较不同组别大鼠甲状腺功能、骨代谢指标、骨密度及血脂相关指标的改变。结果 SCH组大鼠TRACP-5b(F=301.214,P<0.05)、BALP(F=16.432,P<0.05)、BMD(F=8.112,P<0.05)明显低于对照组。胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)高于对照组(P<0.05)。L-T4组大鼠促甲状腺激素(TSH)恢复至正常范围,TRACP-5b、BALP有所升高(P<0.01),TC、LDL-C有不同程度下降(均P<0.05)。相关分析显示,TSH水平与TC(R=0.425,P<0.05)、LDL-C(R=0.228,P<0.05)呈正相关,与BALP(R=-0.297,P<0.05)和TRACP-5b(R=-0.265,P<0.05)呈负相关。结论 SCH是骨质疏松的重要危险因素,可能通过升高TSH抑制骨细胞活性而降低骨密度,L-T4可部分改善实验大鼠骨代谢异常。 Objective The purpose of our study was to observe the changes of bone metabolic markers , bone mineral density and lipid metabolism in subclinical hypothyroidism rats and the effect of L-thyroxine ( L-T4 ) treatment on these changes in the short term.Methods Twenty male Wistar rats SCH, SCH+T4, and control groups were established. Rats in group SCH+T4 received L-T4 replacement treatment to achieve euthyroidism .Results According to our study , SCH rats had higher total cholesterol ( TC) , low-density lipoprotein cholesterol ( LDL-C) levels ( P〈0.05 ) and lower bone mineral density (BMD) (F=8.112, P〈0.05), bone alkaline phosphatase (BALP) (F=16.432, P〈0.05), tartrate resistant acid phosphatase ( TRACP-5b) levels ( F=301.214 , P〈0.05 ) compared to euthyroid subjects .TC, LDL-C decreased and BALP, TRACP-5b levels increased significantly after L-T4 treatment (P〈0.05).TSH was posi-tively correlated with TC ( R=0.425 , P〈0.05 ) , LDL-C ( R=0.228 , P〈0.05 ) and negatively correlated with BALP ( R=-0.297 , P〈0.05 ) and TRACP-5b ( R=-0.265 , P〈0.05 ) .There was no significant change in BMD after the treatment ( P〉0.05 ) .Conclusion We concluded that SCH is closely associated with bone metabolism changes and osteoporosis, which were partly improved by L-T4 treatment.In the short term treatment, the changes of BMD had no sta-tistical significance .
出处 《中华骨质疏松和骨矿盐疾病杂志》 2015年第1期43-47,共5页 Chinese Journal Of Osteoporosis And Bone Mineral Research
基金 国家自然科学基金(81160100 81360125) 甘肃省卫生行业项目科研计划(GSWST2011-01)
关键词 亚临床甲状腺功能减退 骨代谢指标 骨密度 左旋甲状腺素 subclinical hypothyroidism bone metabolism factors bone mineral density L-thyroxine
  • 相关文献

参考文献14

  • 1T6rraga L6pez PJ1, L6pez CF, de Mora FN, et al. Osteo- porosis in patients with subclinical hypothyroidism treated with thyroid hormone [ J ]. Clin Cases Miner Bone Metab, 2011, 8:44-48.
  • 2Eriksen EF. Normal and pathological remodeling of human trabecular bone : three dimensional reconstruction of the re- modeling sequence in normals and in metabolic bone dis- ease [ J]. Endocr Rev, 1986,7:379-408.
  • 3Christenson RH. Biochemical markers of bone metabolism: An overview[J]. Clin Biochem, 1997, 30:573-593.
  • 4Cooper DS, Biondi B. Subclinical thyroid disease [ J ]. Lancet, 2012, 379 : 1142-1154.
  • 5Garin MC, Arnold AM, Lee JS, et al. Subclinical thyroid dysfunction and hip fracture and bone mineral density in ol- der adults: The cardiovascular health study [ J ] J Clin Endocrinol Metab, 2014 : 99:2657-2664.
  • 6NIH Consensus Development Panel on Osteoporosis Preven- tion, Diagnosis, and Therapy. Osteoporosis prevention, di- agnosis, and therapy [J]. JAMA, 2001, 285:785-795.
  • 7田利民,高聆,赵家军.促甲状腺激素的甲状腺外作用[J].国际内分泌代谢杂志,2010,30(3):148-150. 被引量:2
  • 8Abe E, Marians RC, Yu W, et al. Tsh is a negative regu- lator of skeletal remodeling [ J ]. Cell, 2003, 115: 151-162.
  • 9Novack DV. Tsh, the bone suppressing hormone [ J]. Cell, 2003,115 : 129-130.
  • 10Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen [ J]. JAMA, 1994, 271 : 1245-1249.

二级参考文献25

  • 1Davies T,Marians R,Latif R.The TSH receptor reveals itself.J Clin Invest,2002,110:161-164.
  • 2Zhang W,Tian LM,Han Y,et al.Presence of thyrotropin receptor in hepatocytes:Not a case of illegitimate transcription.J Cell Mol Med,2009,13:46364642.
  • 3Douglas RS,Afifiyan NF,Hwang CJ,et al.Increased generation of fibrocytes in thyroid-associated ophthalmopathy.J Clin Endocrinol Metab,2010,95:430-438.
  • 4Kumar S,Schiefer R,Coenen MJ,et al.A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibro-blasts.Thyroid,2010,20:59-65.
  • 5Yin X,Latif R,Bahn R,et al.Influence of the TSH receptor gene on susceptibility to Graves' disease and Craves' ophthalmopathy.Thyroid,2008,18:1201-1206.
  • 6Nannipieri M,Cecchetti F,Anselmino M,et al.Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes:Effects of weight loss.Int J Obes,2009,33:1001-1006.
  • 7Elgadi A.Zemack H,Marcus C,et al.Tissue-specific knockout of TSHr in white adipose tissue increases adipocyte size and decreases TSH-induced lipolysis.Biochem Biophys Res Commun,2010,393:526-530.
  • 8Williams GR.Does serum TSH level have thyroid hormone independent effects on bone turnover? Endocrinology,2009,5:10-11.
  • 9Appetecchia M.Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.Horm Res,2005,64:293-298.
  • 10Panico A,Lupoli GA,Fonderico F,et al.Osteoporosis and thyrot-ropin-suppressive therapy:Reduced effectiveness of alendronate.Thyroid,2009,19:437-442.

共引文献1

同被引文献118

引证文献15

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部